Skip to main content
. 2021 Mar 12;6:35. doi: 10.1038/s41541-021-00300-z

Fig. 3. A/BOL13 serum immune responses are more strongly reduced in multivalent formulations.

Fig. 3

Serum immune responses were measured by HAI and MN assays at Days 7, 14, 21, and 27 post-vaccination. Representative data from Day 21 are shown. a, b HAI and MN data for all strains in A/BOL13 containing formulations. HAI—a (A/BOL13); c (A/SWITZ13); e (B/PHUK13); g (B/BRIS08). MN—b (A/BOL13); d (A/SWITZ13); f (B/PHUK13); h (B/BRIS08). i–p HAI and MN data for all strains in A/NC99 containing formulations. HAI—i (A/NC99); k (A/SWITZ13); m (B/PHUK13); o (B/BRIS08). MN—j (A/NC99); l (A/SWITZ13); n (B/PHUK13); p (B/BRIS08). Bar graphs show geometric mean log2 titers for individual animals (symbols), 4 animals per dose group. Columns and error bars show group geometric mean and group geometric standard deviation. Statistical comparison in all cases was performed by two-way analysis of variance with Sidak’s post-test correcting for multiple comparisons.*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Dotted lines indicate lower limit of detection; values below this were plotted as 0.5× the lower limit of detection. A/BOL13 A/Bolivia/559/2013, A/NC99 A/New Caledonia/20/1999, A/SWITZ13 A/Switzerland/9715293/2013, B/PHUK13 B/Phuket/3073/2013, B/BRIS08 B/Brisbane/60/2008, FFU fluorescent focus units, HAI hemagglutination inhibition, MN microneutralization.